AB1047 FLARE PREVENTION IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS TREATED WITH BELIMUMAB VERSUS STANDARD OF CARE: A PROPENSITY SCORE-MATCHED COMPARATIVE, CASE-CONTROL STUDY

• Published in: Annals of the rheumatic diseases Vol. 83; no. Suppl 1; pp. 1846 - 1847
• Main Authors: Rúa-Figueroa, Í., Altabás González, I., Roberts, K., Casafont-Solé, I., Hernández, A., De la Rubia Navarro, M., Galindo, M., Salman-Monte, T. C., Vidal-Montal, P., Garrote-Corral, S., Blázquez, M. Á., Piqueras Garcia, M. M., Sánchez Lucas, M., Cortés-Hernández, J., De Dios, J. R., Tomero Muriel, E., Vela Casasempere, P., Gandia Martinez, M., Frade-Sosa, B., Ramos Giráldez, C., Moriano, C., Muñoz Jimenez, A., Calvo Alén, J., Menor-Almagro, R., Fernández Nebro, A., Pego-Reigosa, J. M.
• Format: Journal Article
• Language: English
• Published: Kidlington BMJ Publishing Group Ltd and European League Against Rheumatism 01.06.2024; Elsevier B.V; Elsevier Limited
• Subjects: biological DMARD; BLyS protein; Clinical trials; Glucocorticoids; Hydroxychloroquine; Lupus; Monoclonal antibodies; Nephritis; Observational studies/ registry; Prednisone; Proteinuria; Rheumatology; Risk factors; Scientific Abstracts; Standard of care; Statistical analysis; Systemic lupus erythematosus; biological DMARD; Observational studies/ registry

Background:Belimumab (BLM) is a monoclonal antibody targeting BAFF cytokine, which has shown efficacy and safety in the treatment of systemic lupus erythematosus (SLE). A pooled post-hoc analysis from randomized controlled trials BLISS-52 and BLISS-76 suggested that belimumab is effective reducing t...